Miransertib HCl

Miransertib HCl (CAS No.: 1313883-00-9) is a synthetic small-molecule, selective allosteric pan-AKT kinase inhibitor. As a chemical tool compound targeting AKT, a member of the AGC kinase family, it inhibits AKT1, AKT2, and AKT3 and reduces intracellular phosphorylated AKT levels, including in systems engineered to express the activated AKT1 E17K variant, thereby enabling precise analysis of the activation state, feedback regulation, and downstream effect control of the PI3K/AKT signaling pathway; its in vitro biochemical and cellular activities are typically in the low-nanomolar to mid-nanomolar range, with specific values depending on the experimental configuration and cellular background, and are validated by pathway readouts such as inhibition of pAKT. This compound is classified as a tool inhibitor for pathway mechanism elucidation and target function research, mainly serving biomedical research and drug discovery settings, including pathway imaging and functional intervention in tumor-derived cell lines and isogenic engineered cell panels, investigation of pathological signaling drivers in cell models of PI3K/AKT-related overgrowth phenotypes (such as Proteus syndrome), and assessment of host kinase dependence and parasite viability in parasitology research based on its inhibitory activity against Leishmania. Typical applications include target validation, pathway mapping, chemical biology probe studies, and lead compound screening, and it is suitable for multi-level research systems ranging from cellular models to hypothesis-driven animal models; the concentrations or doses used in experiments usually depend on the specific experimental design and research objectives. All of the above uses are limited to research use only and do not involve any clinical or human ingestion-related situations.